On ECHEMI
Home > Drugs > Nosebleeds
Nosebleeds
Epistaxis, also known as nosebleed, is one of the common clinical symptoms. It is mostly caused by nasal lesions, but can also be caused by systemic diseases. Occasionally, bleeding may flow out of the nose due to lesions adjacent to the nasal cavity. Epistaxis is mostly unilateral, but can also be bilateral; it can bleed intermittently or continuously; the amount of bleeding varies, from blood in the mucus in mild cases to hemorrhagic shock in severe cases; repeated bleeding can lead to anemia. Most bleeding can stop on its own.
Related Drugs
Tranexamic acid
Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. This product is also suitable for: 1. Traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 2. Used as an antagonist of tissue plasminogen activator (t→PA), streptokinase, and urokinase. 3. Fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism. 4. Excessive menstruation, hyphema hemorrhage, and severe epistaxis caused by pathologically increased local fibrinolysis in the uterine cavity. 5. Mild bleeding caused by rupture of a central aneurysm, such as subarachnoid hemorrhage and intracranial aneurysm bleeding.
Manufacturer:

Jiangsu Lianhuan Pharmaceutical Co., Ltd.

Tranexamic acid
Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. This product is also suitable for: 1. Traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 2. Used as an antagonist of tissue plasminogen activator (t→PA), streptokinase, and urokinase. 3. Fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism. 4. Excessive menstruation, hyphema hemorrhage, and severe epistaxis caused by pathologically increased local fibrinolysis in the uterine cavity. 5. Mild bleeding caused by rupture of a central aneurysm, such as subarachnoid hemorrhage and intracranial aneurysm bleeding.
Manufacturer:

Changzhou Yinsheng Pharmaceutical Co., Ltd.

Tranexamic acid
Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. This product is also suitable for: 1. Traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 2. Used as an antagonist of tissue plasminogen activator (t→PA), streptokinase, and urokinase. 3. Fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism. 4. Excessive menstruation, hyphema hemorrhage, and severe epistaxis caused by pathologically increased local fibrinolysis in the uterine cavity. 5. Mild bleeding caused by rupture of a central aneurysm, such as subarachnoid hemorrhage and intracranial aneurysm bleeding.
Manufacturer:

Hainan Huluwa Pharmaceutical Group Co., Ltd.

Tranexamic acid
Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. This product is also suitable for: 1. Traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 2. Used as an antagonist of tissue plasminogen activator (t→PA), streptokinase, and urokinase. 3. Fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism. 4. Excessive menstruation, hyphema hemorrhage, and severe epistaxis caused by pathologically increased local fibrinolysis in the uterine cavity. 5. Mild bleeding caused by rupture of a central aneurysm, such as subarachnoid hemorrhage and intracranial aneurysm bleeding.
Manufacturer:

Shanghai Modern Hasen (Shangqiu) Pharmaceutical Co., Ltd.

Rutin Tablets
Indication: It is mainly used for capillary hemorrhage with increased fragility, and is also used as an auxiliary treatment for hypertensive encephalopathy, cerebral hemorrhage, retinal hemorrhage, hemorrhagic purpura, acute hemorrhagic nephritis, recurrent epistaxis, traumatic pulmonary hemorrhage, postpartum hemorrhage, etc.
Manufacturer:

Shanxi Taiyuan Pharmaceutical Co., Ltd.

Ethamethamide injection
Indication: 1. Used to prevent and treat bleeding before and after various surgeries. 2. Can also be used for bleeding caused by poor platelet function and increased vascular fragility, such as thrombocytopenic purpura and allergic purpura. 3. Can also be used for bleeding caused by other reasons, such as cerebral hemorrhage, gastrointestinal bleeding, urinary tract bleeding, fundus bleeding, gingival bleeding, nose bleeding and skin bleeding.
Manufacturer:

Sinopharm Ronshyn Pharmaceutical Co., Ltd.

Ethamethamide injection
Indication: 1. Used to prevent and treat bleeding before and after various surgeries. 2. Can also be used for bleeding caused by poor platelet function and increased vascular fragility, such as thrombocytopenic purpura and allergic purpura. 3. Can also be used for bleeding caused by other reasons, such as cerebral hemorrhage, gastrointestinal bleeding, urinary tract bleeding, fundus bleeding, gingival bleeding, nose bleeding and skin bleeding.
Manufacturer:

Tianjin Pharmaceutical Heping (Tianjin) Pharmaceutical Co., Ltd.

Ethamethamide injection
Indication: 1. Used to prevent and treat bleeding before and after various surgeries. 2. Can also be used for bleeding caused by poor platelet function and increased vascular fragility, such as thrombocytopenic purpura and allergic purpura. 3. Can also be used for bleeding caused by other reasons, such as cerebral hemorrhage, gastrointestinal bleeding, urinary tract bleeding, fundus bleeding, gingival bleeding, nose bleeding and skin bleeding.
Manufacturer:

Anhui Changjiang Pharmaceutical Co., Ltd.

Ethamethamide injection
Indication: 1. Used to prevent and treat bleeding before and after various surgeries. 2. Can also be used for bleeding caused by poor platelet function and increased vascular fragility, such as thrombocytopenic purpura and allergic purpura. 3. Can also be used for bleeding caused by other reasons, such as cerebral hemorrhage, gastrointestinal bleeding, urinary tract bleeding, fundus bleeding, gingival bleeding, nose bleeding and skin bleeding.
Manufacturer:

Fujian Nanshaolin Pharmaceutical Co., Ltd.

Tranexamic acid capsules
Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product should be used with caution before heparinization. This product is also suitable for ① trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, thyroid glands, and liver; ② used as an antagonist of tissue plasminogen activator (tPA), streptokinase, and urokinase; ③ fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism; ④ menorrhagia, hyphema, and severe epistaxis due to local increased fibrinolysis; ⑤ used to prevent or alleviate tooth extraction or
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.